Linking drug target and pathway activation for effective therapy using multi-task learning
暂无分享,去创建一个
Yves Moreau | Julio Saez-Rodriguez | Mi Yang | Jaak Simm | Chi Chung Lam | Pooya Zakeri | Gerard J.P. van Westen
[1] Kazuyuki Kojima,et al. Clinical significance of MET in gastric cancer. , 2015, World journal of gastrointestinal oncology.
[2] Emanuel J. V. Gonçalves,et al. A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.
[3] J. Tait,et al. Challenges and opportunities. , 1996, Journal of psychiatric and mental health nursing.
[4] Davide Corà,et al. VEGF blockade enhances the antitumor effect of BRAFV 600E inhibition , 2016, EMBO molecular medicine.
[5] M. Karin,et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. , 1995, Science.
[6] Nasser Ghadiri,et al. A review of network‐based approaches to drug repositioning , 2018, Briefings Bioinform..
[7] Joshua A. Bittker,et al. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. , 2015, Cancer discovery.
[8] J. Ruland,et al. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. , 2007, Blood.
[9] Jian Jin,et al. Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation , 2016, Science.
[10] P. Lorigan,et al. TNF-α increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes , 2003, British Journal of Cancer.
[11] Sung Kim,et al. HER2‐positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy , 2015, International journal of cancer.
[12] Bob van de Water,et al. MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation , 2015, Genes & cancer.
[13] Julio Saez-Rodriguez,et al. Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties , 2012, PloS one.
[14] Nci Dream Community. A community effort to assess and improve drug sensitivity prediction algorithms , 2014 .
[15] Wei Gu,et al. Dual Roles of MDM2 in the Regulation of p53: Ubiquitination Dependent and Ubiquitination Independent Mechanisms of MDM2 Repression of p53 Activity. , 2012, Genes & cancer.
[16] Krister Wennerberg,et al. Integrative and Personalized QSAR Analysis in Cancer by Kernelized Bayesian Matrix Factorization , 2014, J. Chem. Inf. Model..
[17] J. Trédaniel,et al. Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy , 2013, Front. Endocrin..
[18] Hristo S. Paskov,et al. Multitask learning improves prediction of cancer drug sensitivity , 2016, Scientific Reports.
[19] Krister Wennerberg,et al. Systematic identification of feature combinations for predicting drug response with Bayesian multi-view multi-task linear regression , 2017, Bioinform..
[20] Mehmet Gönen,et al. Drug susceptibility prediction against a panel of drugs using kernelized Bayesian multitask learning , 2014, Bioinform..
[21] Yves Moreau,et al. Macau: Scalable Bayesian factorization with high-dimensional side information using MCMC , 2017, 2017 IEEE 27th International Workshop on Machine Learning for Signal Processing (MLSP).
[22] Joseph A. DiDonato,et al. Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis , 1995, Science.
[23] Edwin Wang,et al. Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets. , 2013, Cell reports.
[24] Adam A. Margolin,et al. Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity , 2012, Nature.
[25] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[26] George Papadatos,et al. Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set , 2017, bioRxiv.
[27] David Meyre,et al. From big data analysis to personalized medicine for all: challenges and opportunities , 2015, BMC Medical Genomics.
[28] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[29] J. Sáez-Rodríguez,et al. Perturbation-response genes reveal signaling footprints in cancer gene expression , 2016, Nature Communications.
[30] G. Robertson,et al. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. , 2010, Biochemical pharmacology.
[31] Mehmet Gönen,et al. Modeling gene‐wise dependencies improves the identification of drug response biomarkers in cancer studies , 2017, Bioinform..
[32] Webster K. Cavenee,et al. Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition , 2015, Oncotarget.
[33] Qiang Yang,et al. A Survey on Transfer Learning , 2010, IEEE Transactions on Knowledge and Data Engineering.
[34] Ivan Babic,et al. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. , 2011, Cancer discovery.
[35] S Marsoni,et al. Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort , 2017, Oncogene.
[36] Isidro Cortes-Ciriano,et al. Current Trends in Drug Sensitivity Prediction. , 2017, Current pharmaceutical design.